Scripps Research scientists launch new digital clinical trial to test repurposed drug for long COVID symptom relief
Study will investigate whether a GIP/GLP-1 dual receptor agonist, currently approved for type 2 diabetes, obesity and obstructive sleep apnea, can reduce symptoms of long COVID.
Read More
RECOVER-TLC workshop on new Long Covid clinical trials
The Sick Times
Long Covid patients can sign up for remote clinical trial notification
Read More
Clinical trial underway for potential Long Covid treatment
Nova Southeastern University and the Schmidt Initiative for Long Covid will study the efficacy of a long-acting antibody for treating Long Covid
Read More
Scientists testing if existing drugs can treat Long Covid
NewsToday.ca